New insider activity at Apellis Pharmaceuticals ( (APLS) ) has taken place on January 15, 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Multiple top executives at Apellis Pharmaceuticals have recently cashed out significant holdings in the company’s stock. Chief Scientific Officer Pascal Deschatelets sold 2,277 shares for $50,503, while Chief Financial Officer Timothy Eugene Sullivan unloaded 3,856 shares worth $85,526. General Counsel David O. Watson sold 5,780 shares for $128,200, and CEO Cedric Francois executed one of the largest insider moves, selling 10,186 shares for $225,925. VP and Chief Accounting Officer James George Chopas sold 873 shares for $19,363, and Chief Technology Officer Nur Nicholson divested 2,618 shares valued at $58,067. Rounding out the wave of insider activity, Chief Business & Strategy Officer Mark Jeffrey DeLong sold 1,780 shares for $39,480. Together, these transactions highlight a broad pattern of stock sales across Apellis’s leadership team.
Recent Updates on APLS stock
In the last 24 hours, Apellis Pharmaceuticals’ shares fell about 17% to roughly $22.58 following the company’s Q4 and full‑year 2025 preliminary revenue pre‑announcement and strategic update given around the JPMorgan healthcare conference. The company reported strong U.S. net product revenue contributions from SYFOVRE and EMPAVELI and highlighted 17% year‑over‑year growth in SYFOVRE injection demand, a robust EMPAVELI launch in C3G/IC‑MPGN with early market penetration, and new pivotal trials in additional nephrology indications, alongside a cash position expected to fund operations to profitability. Despite these positives, analysts’ price target adjustments reflected a more cautious stance: BofA’s modest upward revision was tied to the updated revenue trajectory and business outlook implied by the pre‑announcement, while Cantor Fitzgerald’s reduction stemmed from concern that the company’s decision not to provide formal guidance, even as C3G launches well, introduces added uncertainty and is likely pressuring the stock. Overall, the market reaction indicates that investors are weighing strong product momentum and pipeline expansion against the lack of explicit forward guidance and the risks embedded in Apellis’ long‑term growth path.
Spark’s Take on APLS Stock
According to Spark, TipRanks’ AI Analyst, APLS is a Neutral.
The overall stock score reflects a mixed outlook for Apellis Pharmaceuticals. Financial performance shows improvement, particularly in cash flow, but revenue growth and profitability remain volatile. Technical analysis indicates mixed momentum with potential overbought conditions. The high P/E ratio suggests overvaluation, adding risk if earnings do not meet expectations. The earnings call provided positive guidance, but challenges remain in revenue growth and patient access.
To see Spark’s full report on APLS stock, click here.
More about Apellis Pharmaceuticals
YTD Price Performance: -19.07%
Average Trading Volume: 2,787,412
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.57B